Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Pirtobrutinib in CLL/SLL or NHL
NCT07162181Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2025
- Primary completion
- May 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirtobrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin lymphoma (NHL), sponsored by Eli Lilly and Company. Started Aug 2025; status: active, not recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07162181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162181.